688553.SHG Sichuan Huiyu Pharmaceutical Co Ltd
- Market cap
- CNY 7.14B
- P/E
- 54.3x
- P/B
- 1.78x
- ROE
- 3.1%
- Dividend yield
- 2.79%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688553.SHG undervalued?
Graham number688553.SHG trades 107.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sichuan Huiyu Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Sichuan Huiyu Pharmaceutical Co Ltd yet.
Sichuan Huiyu Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and…
Full company profileSichuan Huiyu Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sichuan Huiyu Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.0M | 54.3M | 707M | 1.36B | 1.82B | 1.49B | 927M | 1.09B | 998M | 1.10B |
| Gross Profit | 1.71M | 41.7M | 657M | 1.24B | 1.66B | 1.31B | 794M | 907M | 998M | 847M |
| Operating Income | -84.3M | -70.6M | 200M | 398M | 479M | 235M | 124M | 348M | -65.0M | 133M |
| EBITDA | -24.0M | -24.4M | 233M | 423M | 514M | 287M | 198M | 440M | 13.4M | 111M |
| Net Income | -84.7M | -22.0M | 177M | 343M | 446M | 249M | 140M | 325M | -24.2M | 115M |
| EPS | -0.23 | -0.06 | 0.42 | 0.95 | 1.20 | 0.59 | 0.33 | 0.77 | -0.06 | 0.18 |
| Balance Sheet | ||||||||||
| Total Assets | 237M | 339M | 860M | 1.21B | 4.13B | 4.28B | 4.69B | 5.17B | 5.02B | 5.20B |
| Total Liabilities | 422M | 490M | 451M | 461M | 571M | 558M | 911M | 1.19B | 1.27B | 1.49B |
| Shareholders' Equity | -185M | -151M | 409M | 751M | 3.56B | 3.72B | 3.77B | 3.98B | 3.76B | 3.73B |
| Cash & Short-term Investments | 4.62M | 45.7M | 437M | 600M | 2.97B | 2.58B | 2.57B | 3.02B | 2.40B | 2.54B |
| Total Debt | 235M | 205M | 56.0M | 11.0M | 20.0M | 55.1M | 429M | 580M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -13.2M | 129M | 326M | 388M | 446M | 194M | 66.9M | 243M | 90.5M | - |
| Capital Expenditure | 7.05M | 23.0M | 110M | 158M | 433M | 462M | 297M | 128M | 105M | 46.6M |
| Free Cash Flow | -20.2M | 106M | 216M | 230M | 12.9M | -268M | -230M | 115M | -14.8M | 136M |
| Ratios | ||||||||||
| ROE | - | - | 43.3% | 45.7% | 12.5% | 6.7% | 3.7% | 8.2% | -0.6% | 3.1% |
| ROA | -35.8% | -6.5% | 20.6% | 28.3% | 10.8% | 5.8% | 3.0% | 6.3% | -0.5% | 2.2% |
| Net Profit Margin | -605.8% | -40.5% | 25.0% | 25.2% | 24.4% | 16.7% | 15.1% | 29.7% | -2.4% | 10.4% |
| Debt to Equity | - | - | 0.14x | 0.01x | 0.01x | 0.01x | 0.11x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sichuan Huiyu Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.79%
- Forward dividend
- 0.20 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 199M | 0.49 | - |
| 2024 | CNY 98.1M | 0.23 | 30.2% |
| 2023 | CNY 99.5M | 0.23 | 71.2% |
| 2022 | CNY 89.4M | 0.21 | 35.9% |
| 2021 | CNY 690K | 0.00 | 0.2% |
| 2020 | CNY 1.87M | 0.01 | 0.5% |
| 2019 | CNY 14.1M | 0.03 | 8.0% |
| 2018 | 48.9M | 0.14 | - |
| 2017 | 9.88M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on Jun 17, 2026.
Who owns Sichuan Huiyu Pharmaceutical Co Ltd
- Insiders 50.72%
- Institutions 4.09%
- Public & others 45.18%
- Shares outstanding 626M
- Free float 357M
Sichuan Huiyu Pharmaceutical Co Ltd company profile
- Company name
- Sichuan Huiyu Pharmaceutical Co Ltd
- Ticker
- 688553.SHG
- ISIN
- CNE100004ZT4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,446
- Fiscal year end
- December
- Address
- Building 3, Neijiang, China, 641000
- Phone
- 86 83 2880 8001
- Website
- huiyupharma.com
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. The company also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, teicoplanin, epirubicin hydrochloride, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Neijiang, China.
Sichuan Huiyu Pharmaceutical Co Ltd management
8- Dr. Zhao DingChairman of the Board & GM · born 1985
- Mr. Lan GaoDirector & Finance Director · born 1971
- Mr. Yong Chun RenEmployee Representative Director & Deputy General Manager · born 1968
- Mr. Chun Ping ZhangDeputy GM, Secretary of the Board & Director · born 1980
- Yan Mei YuAccounting Supervisor
- Mr. Gang CaiManager of Technical Department, Quality Manager & Quality Director · born 1977
- Dr. He Ping HuDirector of the Institute of Chemical Drugs of Huiyu Pharmaceutical Research Institute · born 1977
- Dr. Tao WeiDirector of Institute of Innovative Biopharmaceuticals at Huiyu Pharmaceutical Research Institute · born 1962